Q2 2025 Edwards Lifesciences Corp Earnings Call Transcript
Key Points
- Edwards Lifesciences Corp (EW) reported double-digit sales growth in Q2 2025, with total sales of $1.53 billion, a 10.6% increase, surpassing expectations.
- The company raised its full-year 2025 sales growth guidance to 9% to 10% and adjusted EPS guidance to the high end of the original range of $2.40 to $2.50.
- The Transcatheter Aortic Valve Replacement (TAVR) segment saw global sales increase by 7.8%, driven by the adoption of SAPIEN technology and recent approvals for asymptomatic indications.
- The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment achieved a 57% sales growth, with significant contributions from PASCAL and EVOQUE technologies.
- Edwards Lifesciences Corp (EW) maintains a strong balance sheet with approximately $3 billion in cash and cash equivalents, providing financial flexibility for future investments and share repurchases.
- The company's adjusted gross profit margin decreased to 77.6% from 80% in the same period last year, impacted by additional manufacturing expenses and foreign exchange rates.
- Despite strong performance, the company faces potential headwinds from tariffs and the planned acquisition of JenaValve, which could negatively impact earnings per share.
- The exit of a competitor in Europe presents a challenge in maintaining market share, as Edwards Lifesciences Corp (EW) needs to justify its higher price point compared to competitors.
- The company anticipates increased SG&A spending in the second half of the year, which could pressure operating margins.
- The potential impact of changes in the National Coverage Determination (NCD) for TAVR remains uncertain, which could affect future growth and market dynamics.
Greetings, and welcome to the Edwards Lifesciences second-quarter 2025 results conference call. (Operator Instructions) Please note this conference is being recorded.
I will now turn the conference over to your host, Mark Wilterding, Senior Vice President, Global Finance. Thank you. You may begin.
Thank you very much, Diego, and thank you, all, for joining us this afternoon. With me on today's call is our CEO, Bernard Zovighian; and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call will be Larry Wood, our Global Group President of TAVR and Surgical; Daveen Chopra, our Global Leader of TMTT; Wayne Markowitz, our Global Leader of Surgical; and Dan Lippis, Corporate Vice President. Just after the close of regular trading, Edwards Lifesciences released second-quarter 2025 financial results.
During the call today, management will discuss the results included in the press release and accompanying financial schedules and use
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
